Whole Genome Sequencing for cancer diagnostics clinically validated
Scientific research has demonstrated that Whole Genome Sequencing (WGS) is at least as reliable as routine diagnostic procedures. Clinical Molecular Biologist in Pathology Paul Roepman of Hartwig Medical Foundation in collaboration with national experts in the field recently published this research in The Journal of Molecular Diagnostics.
Measured reliably with a single WGS test
Together with academic partners Antoni van Leeuwenhoek – Netherlands Cancer Institute, Erasmus MC, Radboudumc, UMC Utrecht and Amsterdam UMC, they have shown that the results of WGS for detection of simple mutations, gene amplifications and deletions, and gene fusions are very similar to those of routine diagnostic procedures, with similarly high sensitivity. More complex tumor characteristics such as microsatellite instability (MSI), tumor mutational load and the presence of HPV can also be measured very reliably with a single WGS test.
Independence of the research
As part of the validation of WGS for routine clinical use, results and outcomes were compared one-to-one with the findings of routine diagnostic tests. The academic partners helped to conduct the routine tests for this comparison to ensure the independence of the research. The researchers demonstrated the validity of the various results. For all types of abnormalities, the results of WGS when using frozen samples with sufficient tumor cells (20%) were at least equal to the results obtained with regular diagnostic tests.
WIDE: prospective study to examine the utility of WGS in routine healthcare practice
This clinical validation is an important requirement for adopting new technology in routine healthcare. Meanwhile, researchers are also conducting a prospective study called WIDE to examine the utility of WGS in routine healthcare practice. WIDE stands for WGS Implementation in standard Diagnostic tests for Every cancer patient. The interim analysis of this study has been completed and confirms the clinical validity of WGS, but also revealed that WGS identifies more actionable biomarkers and thus provides additional treatment options for the patient.
Further information
- Paper in The Journal of Molecular Diagnostics: Clinical validation of Whole Genome Sequencing for cancer diagnostics
- Interview with Kim Monkhorst, pathologist at the Netherlands Cancer Institute, on the interim results of WIDE: Whole Genome Sequencing feasible in clinical practice
- Video for physicians and pathologists: OncoAct (in Dutch)
- More information about the comprehensive DNA test: OncoAct.nl
All news
Also read
New cancer treatment options created by full DNA-analysis
Nature publication reports study by Netherlands Center for Personalized Cancer Treatment showing benefits for targeted treatments outside registered indications 2 …
Take a virtual tour of our laboratory: from the biopsy to the patient report
What happens to your tumor tissue and blood during a comprehensive DNA test? What exactly does all the complex equipment …
New CPoC grant awarded: GLOW – GLioblastoma targeted treatment Option maximisation by WGS
Oncode Institute has announced that the 13th grant within the Clinical Proof of Concept programme has been awarded. Oncode Investigator …
I know how important knowledge of hereditary predisposition to cancer can be. This is why I think it is so important that comprehensive patient reports include precisely that carrier information, if the patient wishes to be informed of it.